Terms: = Prostate cancer AND PTPN13, PTP1E, 5783, ENSG00000163629, PTPLE, PTPL1, PNP1, PTP-BAS, DKFZp686J1497, Q12923, FAP-1, PTP-BL AND Prognosis
1 results:
1. Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy.
Bryant AK; D'Amico AV; Nguyen PL; Einck JP; Kane CJ; McKay RR; Simpson DR; Mundt AJ; Murphy JD; Rose BS
Cancer; 2018 Jul; 124(14):2939-2947. PubMed ID: 29727915
[TBL] [Abstract] [Full Text] [Related]
